Susquehanna Fundamental Investments LLC Invests $7.98 Million in Penumbra, Inc. (NYSE:PEN)

Susquehanna Fundamental Investments LLC purchased a new stake in shares of Penumbra, Inc. (NYSE:PEN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 33,584 shares of the company's stock, valued at approximately $7,976,000. Susquehanna Fundamental Investments LLC owned approximately 0.09% of Penumbra at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in PEN. UMB Bank n.a. lifted its position in shares of Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $46,000 after buying an additional 70 shares during the last quarter. Hurley Capital LLC bought a new position in Penumbra in the fourth quarter worth about $56,000. Huntington National Bank boosted its stake in Penumbra by 138.7% in the fourth quarter. Huntington National Bank now owns 265 shares of the company's stock valued at $63,000 after acquiring an additional 154 shares during the period. Mather Group LLC. raised its position in shares of Penumbra by 208.0% during the 4th quarter. Mather Group LLC. now owns 308 shares of the company's stock worth $73,000 after purchasing an additional 208 shares during the period. Finally, Jones Financial Companies Lllp lifted its holdings in shares of Penumbra by 25.0% in the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock worth $89,000 after purchasing an additional 75 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company's stock.

Penumbra Price Performance

Shares of PEN traded up $4.15 during mid-day trading on Friday, hitting $295.97. The company's stock had a trading volume of 382,737 shares, compared to its average volume of 426,931. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The firm has a 50-day moving average price of $276.82 and a 200 day moving average price of $256.96. Penumbra, Inc. has a fifty-two week low of $148.00 and a fifty-two week high of $310.00. The stock has a market capitalization of $11.46 billion, a price-to-earnings ratio of 870.50, a PEG ratio of 2.83 and a beta of 0.56.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating analysts' consensus estimates of $0.66 by $0.17. The company had revenue of $324.14 million during the quarter, compared to the consensus estimate of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company's quarterly revenue was up 16.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.41 EPS. On average, research analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PEN. JPMorgan Chase & Co. upped their price objective on Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. BTIG Research reissued a "buy" rating on shares of Penumbra in a research note on Thursday, April 24th. Truist Financial raised their price target on shares of Penumbra from $315.00 to $330.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Robert W. Baird boosted their price objective on Penumbra from $316.00 to $325.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Finally, Morgan Stanley raised their target price on Penumbra from $240.00 to $260.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 19th. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Penumbra has an average rating of "Moderate Buy" and a consensus price target of $302.40.

Insiders Place Their Bets

In other Penumbra news, CEO Adam Elsesser sold 61,600 shares of Penumbra stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $283.59, for a total transaction of $17,469,144.00. Following the completion of the sale, the chief executive officer now owns 16,376 shares of the company's stock, valued at $4,644,069.84. This trade represents a 79.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Maggie Yuen sold 2,000 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $286.00, for a total value of $572,000.00. Following the completion of the transaction, the chief financial officer now directly owns 15,243 shares in the company, valued at approximately $4,359,498. The trade was a 11.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 140,446 shares of company stock worth $39,543,953. Company insiders own 5.00% of the company's stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.